Le Lézard
Classified in: Health
Subject: v

Extendicare Announces January 2024 Dividend of C$0.04 per Share


MARKHAM, Ontario, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the "Common Share") for the month of January 2024, which is payable on February 15, 2024 to shareholders of record at the close of business on January 31, 2024. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada).

About Extendicare

Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. We are committed to delivering quality care throughout the health continuum to meet the needs of a growing seniors population. We operate or provide managed services to a network of 126 long-term care homes and retirement communities (53 owned/73 managed services), provide approximately 9.7 million hours of home health care services annually, and provide group purchasing services to third parties representing approximately 128,900 beds across Canada. Extendicare proudly employs approximately 22,000 qualified, highly trained and dedicated individuals who are passionate about providing high quality care and services to help people live better.

Forward-looking Statements

Information provided by Extendicare from time to time, including this release, contains or may contain forward-looking statements concerning anticipated future events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation, statements regarding its business operations, business strategy, growth strategy, results of operations and financial condition. Forward-looking statements can often be identified by the expressions "anticipate", "believe", "estimate", "expect", "intend", "objective", "plan", "project", "will", "may", "should" or other similar expressions or the negative thereof. These forward-looking statements reflect the Company's current expectations regarding future results, performance or achievements and are based upon information currently available to the Company and on assumptions that the Company believes are reasonable. The Company assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare's forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare with the securities regulatory authorities, available at www.sedar.com and on Extendicare's website at www.extendicare.com.

Extendicare contact:

Jillian E. Fountain
Vice President, Investor Relations
T: (905) 470-5534
E: [email protected]
www.extendicare.com



These press releases may also interest you

at 09:20
CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has appointed Kathleen Sereda Glaub, MBA, formerly...

at 09:20
The Milken Institute today released a report on artificial intelligence (AI), precision medicine, and neurodegenerative disease. The report will serve as a resource for patient advocates, philanthropists, researchers, policymakers, and industry to...

at 09:15
NeuroSense Therapeutics Ltd.  ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, provided a further update on its plans to file for...

at 09:15
Physicians from Newport Healthcare and PrairieCare, leading providers of evidence-based behavioral healthcare and psychiatric treatment respectively, are set to take the stage at this year's American Academy of Child & Adolescent Psychiatry (AACAP)...

at 09:15
AbsoluteCare, a leader in value-based healthcare, announced today the addition of Michelle Croasdale as Chief Growth Officer. Ms. Croasdale will play a pivotal role in advancing the company's vision to restore the health of all its vulnerable and...

at 09:10
Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with common diseases, today announced that upcoming presentations at the...



News published on and distributed by: